Andere Sprachen Marinomed Biotech AG

Aktien

A2N9MM

ATMARINOMED6

MARI

Verzögert Wiener Boerse Andere Börsenplätze 16:54:06 11.06.2024			% 5 Tage	% 1. Jan.
13,2 ^EUR	+3,12 %		-2,58 %	-54,79 %

22.05.	Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024
21.05.	Marinomed Biotech AG meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Marinomed Biotech : Remuneration policy for members of the Management Board 2024	29.05.
Marinomed Biotech : Remuneration policy for members of the Supervisory Board 2024	29.05.
AGM: Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna time)	23.05.
Marinomed Biotech : Update Q1 2024	22.05.
Marinomed Biotech AG announces results for the first quarter of 2024	22.05.
Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024	21.05.
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios	25.04.
AFR: Marinomed Biotech AG: Release of a Financial report	16.04.
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets	16.04.
AFR: Marinomed Biotech AG: Release of a Financial report	16.04.
Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution	15.04.
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico	11.04.
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months	28.03.
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe	26.03.
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations	01.03.
Marinomed Biotech AG announces preliminary revenue for 2023	14.02.
Marinomed Biotech AG with important progress for Carragelose in 2024	07.02.
Marinomed Biotech Considers Partnerships, Potential Transfer of Carragelose Portfolio	18.12.
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Marinomed Biotech AG

Aktien

A2N9MM

ATMARINOMED6

MARI

Andere Sprachen

Filter